Treatment options for COVID-19: The reality and challenges

Zhou, 2020, Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study, Lancet, 10.1016/S0140-6736(20)30566-3 Cheng, 2020, 2019 Novel coronavirus: where we are and what we know, Infection, 10.1007/s15010-020-01401-y Wu, 2020, Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese Center for Disease Control and Prevention, JAMA, 10.1001/jama.2020.2648 Holshue, 2020, First case of 2019 novel coronavirus in the United States, N Engl J Med, 382, 929, 10.1056/NEJMoa2001191 Lee, 2020, Are children less susceptible to COVID-19?, J Microbiol Immunol Infect, 10.1016/j.jmii.2020.02.011 Huang, 2020, 2019 Novel coronavirus disease (COVID-19) in Taiwan: reports of two cases from Wuhan, China, J Microbiol Immunol Infect, 53, 481, 10.1016/j.jmii.2020.02.009 Burke, 2020, Active monitoring of persons exposed to patients with confirmed COVID-19 - United States, January-February 2020, MMWR Morb Mortal Wkly Rep, 69, 245, 10.15585/mmwr.mm6909e1 Liu, 2020, Neutrophil-to-lymphocyte ratio predicts severe illness patients with 2019 novel coronavirus in the early stage, medRxiv Cao, 2020, SARS-CoV-2 infection in children: transmission dynamics and clinical characteristics, J Formos Med Assoc, 119, 670, 10.1016/j.jfma.2020.02.009 Peiris, 2003, Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study, Lancet, 361, 1767, 10.1016/S0140-6736(03)13412-5 Chen, 2020, Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study, Lancet, 395, 507, 10.1016/S0140-6736(20)30211-7 Hofmann, 2005, Human coronavirus NL63 employs the severe acute respiratory syndrome coronavirus receptor for cellular entry, Proc Natl Acad Sci USA, 102, 7988, 10.1073/pnas.0409465102 Lee, 2019, Characteristics of community-acquired respiratory viruses infections except seasonal influenza in transplant recipients and non-transplant critically ill patients, J Microbiol Immunol Infect, 10.1016/j.jmii.2019.05.007 Lee, 2020, Emerging threats from zoonotic coronaviruses-from SARS and MERS to 2019-nCoV, J Microbiol Immunol Infect, 53, 365, 10.1016/j.jmii.2020.02.001 To, 2020, Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study, Lancet Infect Dis, 10.1016/S1473-3099(20)30196-1 Li, 2020, Therapeutic options for the 2019 novel coronavirus (2019-nCoV), Nat Rev Drug Discov, 19, 149, 10.1038/d41573-020-00016-0 Agostini, 2018, Coronavirus susceptibility to the antiviral remdesivir (GS-5734) Is mediated by the viral polymerase and the proofreading exoribonuclease, mBio, 9, 10.1128/mBio.00221-18 Sheahan, 2017, Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses, Sci Transl Med, 9, 10.1126/scitranslmed.aal3653 Martinez, 2020, Compounds with therapeutic potential against novel respiratory 2019 coronavirus, Antimicrob Agents Chemother, 10.1128/AAC.00399-20 Warren, 2016, Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys, Nature, 531, 381, 10.1038/nature17180 Mulangu, 2019, A randomized, controlled trial of Ebola virus disease therapeutics, N Engl J Med, 381, 2293, 10.1056/NEJMoa1910993 Brown, 2019, Broad spectrum antiviral remdesivir inhibits human endemic and zoonotic deltacoronaviruses with a highly divergent RNA dependent RNA polymerase, Antivir Res, 169, 104541, 10.1016/j.antiviral.2019.104541 Ko, 2020, Arguments in favour of remdesivir for treating SARS-CoV-2 infections, Int J Antimicrob Agents, 105933, 10.1016/j.ijantimicag.2020.105933 de Wit, 2020, Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection, Proc Natl Acad Sci USA, 10.1073/pnas.1922083117 Wang, 2019, Comparative effectiveness of combined favipiravir and oseltamivir therapy versus oseltamivir monotherapy in critically ill patients with influenza virus infection, J Infect Dis Furuta, 2017, Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase, Proc Jpn Acad Ser B Phys Biol Sci, 93, 449, 10.2183/pjab.93.027 XinhuaNet Chan, 2015, Treatment with lopinavir/ritonavir or interferon-β1b improves outcome of MERS-CoV infection in a nonhuman primate model of common marmoset, J Infect Dis, 212, 1904, 10.1093/infdis/jiv392 Zumla, 2016, Coronaviruses - drug discovery and therapeutic options, Nat Rev Drug Discov, 15, 327, 10.1038/nrd.2015.37 Sheahan, 2020, Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV, Nat Commun, 11, 222, 10.1038/s41467-019-13940-6 Cao, 2020, A trial of lopinavir-ritonavir in adults hospitalized with severe COVID-19, N Engl J Med, 10.1056/NEJMoa2001282 Baden, 2020, COVID-19 - the search for effective therapy, N Engl J Med, 10.1056/NEJMe2005477 News Falzarano, 2013, Treatment with interferon-α2b and ribavirin improves outcome in MERS-CoV-infected rhesus macaques, Nat Med, 19, 1313, 10.1038/nm.3362 Chu, 2004, Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings, Thorax, 59, 252, 10.1136/thorax.2003.012658 Yan, 2013, Anti-malaria drug chloroquine is highly effective in treating avian influenza A H5N1 virus infection in an animal model, Cell Res, 23, 300, 10.1038/cr.2012.165 Vincent, 2005, Chloroquine is a potent inhibitor of SARS coronavirus infection and spread, Virol J, 2, 69, 10.1186/1743-422X-2-69 Wang, 2020, Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro, Cell Res, 30, 269, 10.1038/s41422-020-0282-0 Cortegiani, 2020, A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19, J Crit Care, 10.1016/j.jcrc.2020.03.005 Yao, 2020, In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Clin Infect Dis, 10.1093/cid/ciaa237 Gautret, 2020, Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial, Int J Antimicrob Agents, 10.1016/j.ijantimicag.2020.105949 Madrid, 2015, Evaluation of Ebola virus inhibitors for drug repurposing, ACS Infect Dis, 1, 317, 10.1021/acsinfecdis.5b00030 Bacharier, 2015, Early administration of azithromycin and prevention of severe lower respiratory tract illnesses in preschool children with a history of such illnesses: a randomized clinical trial, JAMA, 314, 2034, 10.1001/jama.2015.13896 Wang, 2016, Teicoplanin inhibits Ebola pseudovirus infection in cell culture, Antivir Res, 125, 1, 10.1016/j.antiviral.2015.11.003 Zhou, 2016, Glycopeptide antibiotics potently inhibit cathepsin L in the late endosome/lysosome and block the entry of Ebola virus, Middle East respiratory syndrome coronavirus (MERS-CoV), and Severe Acute Respiratory Syndrome coronavirus (SARS-CoV), J Biol Chem, 291, 9218, 10.1074/jbc.M116.716100 Baron, 2020, Teicoplanin: an alternative drug for the treatment of coronavirus COVID-19?, Int J Antimicrob Agents, 105944, 10.1016/j.ijantimicag.2020.105944 Beigel, 2019, Advances in respiratory virus therapeutics - a meeting report from the 6th isirv Antiviral Group conference, Antivir Res, 167, 45, 10.1016/j.antiviral.2019.04.006 Beigel, 2018, Safety and tolerability of a novel, polyclonal human anti-MERS coronavirus antibody produced from transchromosomic cattle: a phase 1 randomised, double-blind, single-dose-escalation study, Lancet Infect Dis, 18, 410, 10.1016/S1473-3099(18)30002-1 Cockrell, 2016, A mouse model for MERS coronavirus-induced acute respiratory distress syndrome, Nat Microbiol, 2, 16226, 10.1038/nmicrobiol.2016.226 Glowacka, 2011, Evidence that TMPRSS2 activates the severe acute respiratory syndrome coronavirus spike protein for membrane fusion and reduces viral control by the humoral immune response, J Virol, 85, 4122, 10.1128/JVI.02232-10 Kawase, 2012, Simultaneous treatment of human bronchial epithelial cells with serine and cysteine protease inhibitors prevents severe acute respiratory syndrome coronavirus entry, J Virol, 86, 6537, 10.1128/JVI.00094-12 Zhou, 2015, Protease inhibitors targeting coronavirus and filovirus entry, Antivir Res, 116, 76, 10.1016/j.antiviral.2015.01.011 News Chen, 2020, Convalescent plasma as a potential therapy for COVID-19, Lancet Infect Dis, 10.1016/S1473-3099(20)30141-9 Shen, 2020, Treatment of 5 critically ill patients with COVID-19 with convalescent plasma, JAMA, 10.1001/jama.2020.4783 Cunningham, 2020, Treatment of COVID-19: old tricks for new challenges, Crit Care, 24, 91, 10.1186/s13054-020-2818-6 Luo, 2020, Can Chinese medicine be used for prevention of corona virus disease 2019 (COVID-19)? A review of historical classics, research evidence and current prevention programs, Chin J Integr Med, 10.1007/s11655-020-3192-6 Lai CC, Wang CY, Hsueh PR.Co-infection among patients with COVID-19.(manuscript submitted). Chou, 2019, Recommendations and guidelines for the treatment of pneumonia in Taiwan, J Microbiol Immunol Infect, 52, 172, 10.1016/j.jmii.2018.11.004 Jean, 2020, Epidemiology, treatment, and prevention of nosocomial bacterial pneumonia, J Clin Med, 9, 275, 10.3390/jcm9010275 Yang, 2020, Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study, Lancet Respir Med, 10.1016/S2213-2600(20)30079-5 Guan, 2020, Clinical characteristics of coronavirus disease 2019 in China, N Engl J Med, 10.1056/NEJMoa2002032 Fang, 2020, Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection?, Lancet Respir Med, 10.1016/S2213-2600(20)30116-8 Day, 2020, COVID-19: ibuprofen should not be used for managing symptoms, say doctors and scientists, BMJ, 368, m1086, 10.1136/bmj.m1086 Society of Critical Care Medicine Wu, 2020, Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China, JAMA Intern Med, 10.1001/jamainternmed.2020.0994 Tang, 2020, Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy, J Thromb Haemost, 10.1111/jth.14817 Wösten-van Asperen, 2013, Imbalance between pulmonary angiotensin-converting enzyme and angiotensin-converting enzyme 2 activity in acute respiratory distress syndrome, Pediatr Crit Care Med, 14, e438, 10.1097/PCC.0b013e3182a55735 Fedson, 2016, Treating the host response to emerging virus diseases: lessons learned from sepsis, pneumonia, influenza and Ebola, Ann Transl Med, 4, 421, 10.21037/atm.2016.11.03 Fedson, 2020, Hiding in plain sight: an approach to treating patients with severe COVID-19 infection, mBio, 11, 10.1128/mBio.00398-20